BARCELONA — Only the second head-to-head trial to directly compare two new classes of type 2 diabetes drugs, a GLP-1 agonist with an SGLT2 inhibitor, shows the former, in this case once-weekly ...

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and ...

When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...

Metformin displayed lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had highest risk. (HealthDay News) — Compared with other antidiabetic classes, metformin and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SGLT2 inhibitors cut the risk for adverse CV outcomes ...

Please provide your email address to receive an email when new articles are posted on . Sodium-glucose cotransporter 2 inhibitors were linked with higher likelihood of MASLD regression. Lower ...

Patients with type 2 diabetes who start SGLT2 inhibitors and then develop a urinary or genital tract infection are more ...

Tirzepatide's uptake was rapid post-launch, surpassing other GLP-1 RAs and SGLT2 inhibitors, while conventional GLMs like metformin and insulin declined. The approval of tirzepatide for type 2 ...

Analysis of more than 1.5 million records of patients with type 2 diabetes casts light on the risk of dementia and Alzheimer’s disease and potential benefits associated with antidiabetic treatment, ...